Leerink Partners Starts Cartesian Therapeutics (RNAC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Price: $6.49 -3.85%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Leerink Partners analyst Thomas Smith initiates coverage on Cartesian Therapeutics (NASDAQ: RNAC) with a Outperform rating and a price target of $39.00.
For an analyst ratings summary and ratings history on Cartesian Therapeutics click here. For more ratings news on Cartesian Therapeutics click here.
Shares of Cartesian Therapeutics closed at $18.26 yesterday.
You May Also Be Interested In
- Tigress Financial Partners Resumes Southwest (LUV) at Buy
- StoneX Starts Origin Bancorp (OBK) at Hold
- Maxim Group Starts Legacy Reserves (LGCY) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
